Brentuximab vedotin

Brentuximab vedotin
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (mouse/human)
Target	CD30
Clinical data
Trade names	Adcetris
Other names	SGN-35, previously cAC10-vcMMAE
AHFS/Drugs.com	Monograph
MedlinePlus	a611052
License data	US DailyMed: Brentuximab;
Pregnancy; category	AU: D;
Routes of; administration	Intravenous
ATC code	L01FX05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	914088-09-8 ;
DrugBank	DB08870 ;
ChemSpider	none;
UNII	7XL5ISS668;
Chemical and physical data
Formula	C6476H9930N1690O2030S40 (C68H105N11O15)3–5
Molar mass	149.2–151.8 kg/mol
	(what is this?) (verify)

Brentuximab vedotin, sold under the brand name Adcetris, is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.^[3] The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seagen in the US.^[4]

^ Cite error: The named reference Adcetris FDA label was invoked but never defined (see the help page).
^ Cite error: The named reference Adcetris EPAR was invoked but never defined (see the help page).
^ "Seattle Genetics Submits BLA to FDA for brentuximab vedotin in relapsed or refractory hodgkin lymphoma and systemic ALCL". Fierce Biotech. 28 February 2011.
^ "Takeda and Millennium Announce Approval of Adcetris (Brentuximab Vedotin) in Switzerland". www.takedaoncology.com. Archived from the original on 4 June 2020. Retrieved 4 June 2020.

[Adcetris_FDA_label-1] Cite error: The named reference Adcetris FDA label was invoked but never defined (see the help page).

[Adcetris_EPAR-2] Cite error: The named reference Adcetris EPAR was invoked but never defined (see the help page).

[3] "Seattle Genetics Submits BLA to FDA for brentuximab vedotin in relapsed or refractory hodgkin lymphoma and systemic ALCL". Fierce Biotech. 28 February 2011.

[4] "Takeda and Millennium Announce Approval of Adcetris (Brentuximab Vedotin) in Switzerland". www.takedaoncology.com. Archived from the original on 4 June 2020. Retrieved 4 June 2020.

[1]

[2]

[3]

[4]